MediCor Ltd. Reports Results for First Quarter Fiscal 2006

LAS VEGAS, Nov. 14  /PRNewswire-FirstCall/ -- Las Vegas-based MediCor Ltd. (OTC:MDCR) (BULLETIN BOARD: MDCR) , the world's third largest manufacturer and distributor of breast implants, today announced results for its first fiscal quarter ended September 30, 2005.

Sales for the three months ended September 30, 2005 were $5,662,015, a decrease of $481,044 or 7.8% as compared to the prior year quarter.  While overall unit sales remained about flat compared to the same quarter in the prior year, average selling prices declined primarily due to price competition in Europe.  Net loss for the quarter ended September 30, 2005 decreased to $3,742,600 from $3,830,028 in the comparable period in 2004.  Basic and diluted loss per share for the quarter ended September 30, 2005 was ($0.20) compared to ($0.21) for the quarter ended September 30, 2004.

Theodore R. Maloney, MediCor's Chief Executive Officer, stated, "Our first fiscal quarter of 2006 produced enormous strides for the Company and its aggressive growth strategy.  In addition to success in maintaining our targeted market share gains, we announced a definitive agreement to acquire Biosil Limited and Nagor Limited, the United Kingdom-based manufacturer and distributor of saline and silicone breast and other implants.  We expect the transaction to close prior to the end of this calendar year and to further strengthen our position as the clear number three competitor in the global market for breast implants, as well as provide us with a larger base from which to grow and also sustain temporary pricing actions from our competitors of the kind we saw during the past quarter.  We are also moving forward with our longer term plans to address the U.S. marketplace.  Our investment in clinical trials for our saline implants continues and during the quarter we also advanced our plans to file for an investigational device exemption, or IDE, as a first step on the road to U.S. approval for our high-consistency silicone implants."

According to David Barella, Executive Vice President of International Marketing and Sales, "The decrease in selling prices in Europe was primarily due to competition exacerbated somewhat by weaker economic conditions in the region.  As we actively gained market share over the past three quarters, we anticipated an aggressive response from our competitors, which came in the form of price competition.  Our latest four quarter sales growth rate, including the recent quarter, was approximately 10%, which we believe represents continuing gains in our market share.  We have already initiated an innovative new marketing program specifically designed to add significant value to our products and differentiate us from the competition.  We are confident that the market will recognize the new value that we have put in place and, as a result, we expect that our historic trend of sales growth and market share gains will continue."

About MediCor Ltd.

MediCor was founded by Chairman of the Board Donald K. McGhan, the pioneer of the modern day breast implant industry.  The Company acquires, develops, manufactures and markets products for medical specialties in aesthetic, plastic and reconstructive surgery and dermatology markets.  Products include surgically implantable prostheses for aesthetic, plastic and reconstructive surgery and scar management products.  Its products are sold worldwide to hospitals, surgery centers and physicians through various distributors and direct sales personnel. MediCor's strategy is to be the leading integrator of selected international medical device markets, technologies and corporations. To achieve this strategy, MediCor intends to build upon and expand its business lines, primarily in the aesthetic, plastic and reconstructive surgery and dermatology markets.  MediCor intends to accomplish this growth through the expansion of existing product lines and offerings and through the acquisition of companies and other assets, including intellectual property rights or distribution rights.

Forward-Looking Statements

This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Such statements are based upon the current beliefs and expectations of MediCor's management and are subject to significant risks and uncertainties.  Actual results may differ from those set forth in the forward-looking statements.

The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the ability to obtain requisite financing for acquisitions to continue to execute on our growth plans, the risk of instability in the capital markets in the U.S. and internationally, the ability to obtain governmental approvals to market the company's products and the timing of the company's and its competitors' approvals and entry to markets needed to operate our businesses; the risk that businesses we acquire will not be integrated successfully; the risk that cost savings from acquisition transactions may not be realized or may take longer to realize than expected; disruption from transactions making it more difficult to maintain relationships with customers, employees or suppliers; increased competition and its effect on pricing, spending, third-party relationships and revenues; the outcome of legal proceedings; the risk of new and changing regulations in the U.S. and internationally.  Additional factors that could cause MediCor's results to differ materially from those described in the forward-looking statements can be found in MediCor's Annual Report on Form 10-KSB for the year ended June 30, 2005, which was filed with the Securities and Exchange Commission and is available at the Securities and Exchange Commission's Internet site (http://www.sec.gov/). 

DATASOURCE: MediCor Ltd.



CONTACT:  Marc S. Sperberg of MediCor Ltd., [phone], ext. 308; or

Mark Collinson of CCG Investor Relations, [phone], ext. 117, for

MediCor Ltd.

Copyright